• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $XFOR

    X4 Pharmaceuticals Inc.

    Subscribe to $XFOR
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rear diseases. Its lead product candidate is mavorixafor, an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat patients suffering from chronic rare diseases. X4 Pharmaceuticals, Inc. has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

    IPO Year: 2017

    Exchange: NASDAQ

    Website: x4pharma.com

    Peers

    $BCRX
    $DCPH
    $RYTM

    Recent Analyst Ratings for X4 Pharmaceuticals Inc.

    DatePrice TargetRatingAnalyst
    12/12/2023$3.00 → $1.00Buy → Neutral
    B. Riley Securities
    8/30/2023$3.00Buy
    B. Riley Securities
    12/22/2022$3.00Overweight
    Cantor Fitzgerald
    12/12/2022$3.00Overweight
    Piper Sandler
    12/14/2021$21.00 → $11.00Buy
    HC Wainwright & Co.
    See more ratings

    X4 Pharmaceuticals Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Arbet-Engels Christophe was granted 850,000 shares, increasing direct ownership by 5,983% to 864,207 units (SEC Form 4)

      4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)

      2/14/25 4:09:09 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Mostafa Adam S. was granted 850,000 shares (SEC Form 4)

      4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)

      2/14/25 4:08:54 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Ragan Paula was granted 2,250,000 shares, increasing direct ownership by 207% to 3,337,386 units (SEC Form 4)

      4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)

      2/14/25 4:08:38 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Operating Officer Dibiase Mary was granted 650,000 shares, increasing direct ownership by 132% to 1,140,980 units (SEC Form 4)

      4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)

      2/14/25 4:08:16 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Commercial Officer Baldry Mark bought $19,252 worth of shares (35,050 units at $0.55) and was granted 600,000 shares, increasing direct ownership by 675% to 729,173 units (SEC Form 4)

      4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)

      2/14/25 4:08:25 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Ragan Paula was granted 169,940 shares and sold $34,719 worth of shares (76,473 units at $0.45), increasing direct ownership by 9% to 1,087,386 units (SEC Form 4)

      4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)

      1/27/25 6:15:54 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Mostafa Adam S. was granted 74,773 shares and sold $33,947 worth of shares (74,773 units at $0.45) (SEC Form 4)

      4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)

      1/27/25 6:15:43 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Commercial Officer Baldry Mark was granted 74,773 shares and sold $13,241 worth of shares (29,159 units at $0.45), increasing direct ownership by 94% to 94,123 units (SEC Form 4)

      4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)

      1/27/25 6:15:32 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Operating Officer Dibiase Mary was granted 61,178 shares and sold $10,094 worth of shares (22,258 units at $0.45), increasing direct ownership by 9% to 490,980 units (SEC Form 4)

      4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)

      1/27/25 6:15:24 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Medical Officer Arbet-Engels Christophe was granted 25,831 shares and sold $5,284 worth of shares (11,624 units at $0.45) (SEC Form 4)

      4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)

      1/27/25 6:15:12 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    X4 Pharmaceuticals Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

      4WARD Phase 3 chronic neutropenia trial in full swing; full enrollment on track for 3Q or 4Q 2025 and top-line data in 2H 2026 Additional analyses of mavorixafor clinical trial data increase confidence in successful outcome of 4WARD trial XOLREMDI® net U.S. revenues $3.5 million since May 2024 launch Conference call and webcast today at 8:30 am ET BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the first quarter ended March 31, 2025, and highlighted key recent events and expected upcoming milestones. "The first quarter of 2025 was an

      5/1/25 6:01:00 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025

      BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the first quarter ended March 31, 2025 and provide corporate updates on Thursday, May 1, 2025. The company will host a conference call and webcast on the same day at 8:30 a.m. EDT. The conference call can be accessed by dialing 1-800-343-4849 from the United States or 1-203-518-9848 internationally, followed by the conference ID: X4PHARMA. The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals' website at www.x4pharma.com. Foll

      4/24/25 8:03:00 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • X4 Pharmaceuticals Announces Reverse Stock Split

      BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that its board of directors has determined to effect a one-for-thirty reverse stock split of the company's Common Stock, par value $0.001 per share. The reverse stock split will take effect at 12:01 a.m. Eastern Time on April 28, 2025, and the company's Common Stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market as of the opening of trading on April 28, 2025. The CUSIP number of 98420X202 will be assigned to the company's Common Stock when the reverse stock split becomes effective.

      4/24/25 8:00:00 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on January 31, 2025, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the "2019 Inducement Plan"). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 450,471 shares of X4's common stock. These stock awards were granted as an inducement material to the new employees ent

      4/23/25 4:05:00 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line data anticipated in 2H 2026 4WARD trial protocol refined, increasing confidence in successful outcome 2024 XOLREMDI® net revenues $2.6 million since May launch; company expects ramp up in 2025 as targeted physician outreach increases patient finding and pull-through Conference call and webcast today at 8:30 am ET BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the fourth quarter and full year

      3/25/25 6:01:00 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

      BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024 and provide corporate updates on Tuesday, March 25, 2025. The company will host a conference call and webcast on the same day at 8:30 a.m. ET. The conference call can be accessed by dialing 1-800-267-6316 from the United States or 1-203-518-9783 internationally, followed by the conference ID: X4PHARMA. The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals' website at www

      3/11/25 8:00:00 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries

      BOSTON and DUBAI, United Arab Emirates, Feb. 19, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, and taiba rare, a taiba Healthcare company with specialty & orphan drug marketing, sales, and distribution expertise in the MENA (Middle East and North Africa) region, today announced that they have entered into an exclusive agreement for the distribution and commercialization of XOLREMDI® (mavorixafor), an oral, once-daily treatment for WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis), in select Middle East countries (Saudi Arabia, United Arab Emirates, Qatar, Oman, Kuw

      2/19/25 7:35:00 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

      Full enrollment in ongoing global, pivotal Phase 3 clinical trial in chronic neutropeniaon track for mid-2025 Right-sizing commercial efforts to optimize XOLREMDI promotion and support U.S. WHIM syndrome community Restructuring impact expected to extend cash runway into first half of 2026 BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, announced today a restructuring of its workforce and capital spending to focus efforts on advancing mavorixafor to treat those with chronic neutropenia, while also optimizing its U.S. promotion of XOLREMDI® (mavorixafor), approved for the t

      2/6/25 7:35:00 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on January 31, 2025, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the "2019 Inducement Plan"). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 130,117 shares of X4's common stock. These stock awards were granted as an inducement material to the new employees ente

      2/3/25 4:05:00 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

      Submission supported by positive results from global, Phase 3 4WHIM clinical trial; U.S. regulatory approval in WHIM syndrome granted in 2024 Decision on MAA expected in 1H 2026 BOSTON, Jan. 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that its Marketing Authorization Application (MAA) for mavorixafor for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis), a rare primary immunodeficiency, has been validated for review and is now under evaluation with the European Medicines Agency's (EMA) Committee for Medicinal Products

      1/24/25 7:36:00 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    X4 Pharmaceuticals Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by X4 Pharmaceuticals Inc.

      10-Q - X4 Pharmaceuticals, Inc (0001501697) (Filer)

      5/1/25 9:22:18 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • X4 Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - X4 Pharmaceuticals, Inc (0001501697) (Filer)

      5/1/25 6:25:29 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by X4 Pharmaceuticals Inc.

      DEF 14A - X4 Pharmaceuticals, Inc (0001501697) (Filer)

      4/25/25 4:44:31 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by X4 Pharmaceuticals Inc.

      DEFA14A - X4 Pharmaceuticals, Inc (0001501697) (Filer)

      4/25/25 4:07:42 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • X4 Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

      8-K - X4 Pharmaceuticals, Inc (0001501697) (Filer)

      4/24/25 8:57:49 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • X4 Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - X4 Pharmaceuticals, Inc (0001501697) (Filer)

      4/18/25 4:18:58 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by X4 Pharmaceuticals Inc.

      S-8 - X4 Pharmaceuticals, Inc (0001501697) (Filer)

      3/26/25 6:12:43 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by X4 Pharmaceuticals Inc.

      10-K - X4 Pharmaceuticals, Inc (0001501697) (Filer)

      3/25/25 6:16:46 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • X4 Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - X4 Pharmaceuticals, Inc (0001501697) (Filer)

      3/25/25 7:51:28 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by X4 Pharmaceuticals Inc.

      DEF 14A - X4 Pharmaceuticals, Inc (0001501697) (Filer)

      3/24/25 4:43:21 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    X4 Pharmaceuticals Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • X4 Pharmaceuticals downgraded by B. Riley Securities with a new price target

      B. Riley Securities downgraded X4 Pharmaceuticals from Buy to Neutral and set a new price target of $1.00 from $3.00 previously

      12/12/23 8:15:43 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • B. Riley Securities resumed coverage on X4 Pharmaceuticals with a new price target

      B. Riley Securities resumed coverage of X4 Pharmaceuticals with a rating of Buy and set a new price target of $3.00

      8/30/23 7:46:17 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on X4 Pharmaceuticals with a new price target

      Cantor Fitzgerald initiated coverage of X4 Pharmaceuticals with a rating of Overweight and set a new price target of $3.00

      12/22/22 7:56:33 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler initiated coverage on X4 Pharmaceuticals with a new price target

      Piper Sandler initiated coverage of X4 Pharmaceuticals with a rating of Overweight and set a new price target of $3.00

      12/12/22 8:18:10 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on X4 Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of X4 Pharmaceuticals with a rating of Buy and set a new price target of $11.00 from $21.00 previously

      12/14/21 6:08:19 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    X4 Pharmaceuticals Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    X4 Pharmaceuticals Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    X4 Pharmaceuticals Inc. Financials

    Live finance-specific insights

    See more

    X4 Pharmaceuticals Inc. FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • Chief Commercial Officer Baldry Mark bought $19,252 worth of shares (35,050 units at $0.55) and was granted 600,000 shares, increasing direct ownership by 675% to 729,173 units (SEC Form 4)

      4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)

      2/14/25 4:08:25 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by X4 Pharmaceuticals Inc.

      SC 13G/A - X4 Pharmaceuticals, Inc (0001501697) (Subject)

      11/12/24 5:59:35 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by X4 Pharmaceuticals Inc.

      SC 13G/A - X4 Pharmaceuticals, Inc (0001501697) (Subject)

      11/4/24 2:15:54 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by X4 Pharmaceuticals Inc. (Amendment)

      SC 13G/A - X4 Pharmaceuticals, Inc (0001501697) (Subject)

      2/14/24 7:36:59 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by X4 Pharmaceuticals Inc.

      SC 13G - X4 Pharmaceuticals, Inc (0001501697) (Subject)

      2/14/24 4:44:14 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by X4 Pharmaceuticals Inc. (Amendment)

      SC 13G/A - X4 Pharmaceuticals, Inc (0001501697) (Subject)

      2/14/24 4:32:42 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by X4 Pharmaceuticals Inc. (Amendment)

      SC 13G/A - X4 Pharmaceuticals, Inc (0001501697) (Subject)

      2/13/24 6:55:56 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by X4 Pharmaceuticals Inc. (Amendment)

      SC 13G/A - X4 Pharmaceuticals, Inc (0001501697) (Subject)

      2/7/24 5:09:04 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by X4 Pharmaceuticals Inc.

      SC 13G - X4 Pharmaceuticals, Inc (0001501697) (Subject)

      1/31/24 2:08:26 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by X4 Pharmaceuticals Inc. (Amendment)

      SC 13G/A - X4 Pharmaceuticals, Inc (0001501697) (Subject)

      1/16/24 4:18:56 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by X4 Pharmaceuticals Inc. (Amendment)

      SC 13G/A - X4 Pharmaceuticals, Inc (0001501697) (Subject)

      1/8/24 10:26:16 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

      4WARD Phase 3 chronic neutropenia trial in full swing; full enrollment on track for 3Q or 4Q 2025 and top-line data in 2H 2026 Additional analyses of mavorixafor clinical trial data increase confidence in successful outcome of 4WARD trial XOLREMDI® net U.S. revenues $3.5 million since May 2024 launch Conference call and webcast today at 8:30 am ET BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the first quarter ended March 31, 2025, and highlighted key recent events and expected upcoming milestones. "The first quarter of 2025 was an

      5/1/25 6:01:00 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025

      BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the first quarter ended March 31, 2025 and provide corporate updates on Thursday, May 1, 2025. The company will host a conference call and webcast on the same day at 8:30 a.m. EDT. The conference call can be accessed by dialing 1-800-343-4849 from the United States or 1-203-518-9848 internationally, followed by the conference ID: X4PHARMA. The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals' website at www.x4pharma.com. Foll

      4/24/25 8:03:00 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line data anticipated in 2H 2026 4WARD trial protocol refined, increasing confidence in successful outcome 2024 XOLREMDI® net revenues $2.6 million since May launch; company expects ramp up in 2025 as targeted physician outreach increases patient finding and pull-through Conference call and webcast today at 8:30 am ET BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the fourth quarter and full year

      3/25/25 6:01:00 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

      BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024 and provide corporate updates on Tuesday, March 25, 2025. The company will host a conference call and webcast on the same day at 8:30 a.m. ET. The conference call can be accessed by dialing 1-800-267-6316 from the United States or 1-203-518-9783 internationally, followed by the conference ID: X4PHARMA. The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals' website at www

      3/11/25 8:00:00 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

      Positive results from completed Phase 2 study of mavorixafor in chronic neutropenia (CN) announced today Pivotal Phase 3 trial of mavorixafor in CN on track to fully enroll in mid-2025 U.S. launch of XOLREMDI® (mavorixafor) in WHIM underway; submission of Marketing Authorization Application (MAA) to European Medicines Agency (EMA) expected by early 2025 Conference call and webcast today at 8:00 a.m. ET BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the third quarter ended September 30, 2024 and highlighted recent and key upcoming ex

      11/13/24 6:07:00 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

      Mavorixafor durably and meaningfully elevated participants' mean absolute neutrophil counts (ANC) Mavorixafor enabled substantial reductions in G-CSF dosing while maintaining mean ANC at normal levels Phase 2 study results and new analysis confirming functionality of neutrophils in sub-study participants bolster confidence in achieving success in Phase 3 4WARD trial Company conference call and webcast today at 8:00 am ET BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced positive new clinical data from its now completed Phase 2 clinical trial evaluating mav

      11/13/24 6:01:00 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024

      BOSTON, Oct. 24, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the third quarter ended September 30, 2024 and present results from its concluded Phase 2 clinical trial evaluating mavorixafor in people with chronic neutropenia on Wednesday, November 13, 2024. The company will host a conference call and webcast on the same day at 8:00 a.m. ET. The conference call can be accessed by dialing 1-800-267-6316 from the United States or 1-203-518-9783 internationally, followed by the conference ID: X4PHARMA. The live webcast and accom

      10/24/24 8:00:00 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

      First U.S. commercial sales of XOLREMDI™ (mavorixafor) following April 2024 FDA approval Positive interim data from Phase 2 trial of mavorixafor in chronic neutropenia; full trial results expected in November 2024 Initiated global, pivotal Phase 3 trial of mavorixafor in chronic neutropenia Conference call to be hosted today at 8:30 a.m. ET BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the second quarter ended June 30, 2024 and highlighted key recent and upcoming expected milestones. Paula Ragan, Ph.D., President and Chief Executi

      8/8/24 6:01:00 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • X4 Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host a Conference Call and Webcast on August 8, 2024

      BOSTON, July 30, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the second quarter ended June 30, 2024 and provide corporate updates on Thursday, August 8, 2024. The company will host a conference call and webcast on the same day at 8:30 a.m. ET. The conference call can be accessed by dialing 1-800-225-9448 from the United States or 1-203-518-9708 internationally, followed by the conference ID: X4PHARMA. The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals' website at www.x4pharma.co

      7/30/24 8:00:00 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

      U.S. launch underway for XOLREMDI™ (mavorixafor) in WHIM syndrome XOLREMDI Phase 3 4WHIM clinical trial data published online in Blood, the journal of the American Society of Hematology Presentation of interim clinical data from the ongoing mavorixafor Phase 2 trial in chronic neutropenia expected at a planned company investor event in June 2024 Conference call to be hosted today at 8:30 a.m. ET BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the first quarter ended March 31, 2024 and hig

      5/7/24 6:01:00 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for XOLREMDI issued to X4 PHARMACEUTICALS INC

      Submission status for X4 PHARMACEUTICALS INC's drug XOLREMDI (ORIG-1) with active ingredient MAVORIXAFOR has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218709, Application Classification: Type 1 - New Molecular Entity

      4/29/24 2:36:51 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    X4 Pharmaceuticals Inc. Leadership Updates

    Live Leadership Updates

    See more
    • X4 Pharmaceuticals Announces Appointment of Industry Veteran R. Keith Woods to Board of Directors

      BOSTON, Oct. 18, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced the appointment of R. Keith Woods as an independent director to the company's Board of Directors. "We are thrilled to welcome Keith to the X4 Board of Directors," said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals. "With his broad and deep experience in commercialization, international operations, supply chain, and business strategy, as well as his recent successful global launch of a rare disease product, we believe it is a great time for him to be joining X4 as a director a

      10/18/23 8:00:00 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • X4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial Officer

      A seasoned leader in the launch of rare and specialty pharmaceuticals, Mr. Baldry is expected to join X4 on November 3, 2022 BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, today announced the appointment of Mark Baldry to the position of Chief Commercial Officer. In this key role, Mr. Baldry will lead all pre-commercial and product launch efforts for the company's lead therapeutic candidate, mavorixafor, a small molecule being developed as a once-daily oral therapy for chronic neutropenic disorders, including WHIM syndrome.

      10/26/22 8:00:00 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer

      WALTHAM, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced the appointment of Carrie Melvin as Chief Operating Officer, a newly created position at the company. "As we prepare for late-stage clinical development for our TED programs, we are excited to add Carrie to the Viridian team" said Jonathan Violin, Ph.D., Viridian Therapeutics' President and CEO. "Carrie's extensive experience in a wide range of operational activities supporting product development and approval will be tremendously valuable to our expanding

      6/23/22 7:00:00 AM ET
      $GSK
      $KURA
      $VRDN
      $XFOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Specialities
      Biotechnology: Biological Products (No Diagnostic Substances)
    • X4 Pharmaceuticals Expands Commercial Leadership Expertise with Appointment of Françoise de Craecker to Board of Directors and Karolyn Park as Vice President, U.S. Commercial

      BOSTON, Oct. 19, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with diseases of the immune system, announced today the appointment of Françoise de Craecker to the company's Board of Directors and the recent hiring of Karolyn Park to the newly created role of Vice President, U.S. Commercial, significantly strengthening the company's depth and breadth of commercial leadership experience. Ms. de Craecker's appointment expands the X4 Board of Directors to nine members. "With the first pivotal trial of our lead candidate mavorixafor now fully enrolled, we believe

      10/19/21 8:00:00 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BOSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that, on December 31, 2020, the Compensation Committee of X4’s Board of Directors issued an inducement award to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 156,050 shares of X4’s common stock an

      1/4/21 4:01:00 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • X4 Pharmaceuticals Appoints Diego Cadavid, M.D., as Chief Medical Officer

      BOSTON, Dec. 14, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced the appointment of Diego Cadavid, M.D., as Chief Medical Officer. Dr. Cadavid will be responsible for the strategy, direction and execution of the company's clinical development programs. “We are very pleased to welcome Diego to our team,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals. “We believe his strong clinical development expertise, in particular with the advancement of small molecules and biologics for the treatment of

      12/14/20 8:00:00 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that, on November 30, 2020, the Compensation Committee of X4’s Board of Directors issued an inducement award to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 125,950 shares of X4’s common stock an

      12/1/20 4:01:00 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care